patent infringement

Health Tech

AliveCor Isn’t Backing Down from Apple, Its ‘Bully’

AliveCor CEO Priya Abani argues that Apple has made a habit of taking intellectual property from smaller medical device firms in order to improve the functionalities its Apple Watch. She also believes that Apple has been able to avoid taking accountability for this by “bombarding” smaller companies with litigation it knows they won’t be able to afford — a claim that medical IP lawyers have backed up.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.


Two views: Diagnostics firms may be worried but there are Prometheus write arounds

The biotech industry has moved swiftly to decry the Supreme Court’s Prometheus decision where the nine justices ruled unanimously  in favor of  Mayo Clinic that natural bodily responses to medical treatment are not patent eligible. In an interview with MedCity News, Kevin Noonan, a partner with intellectual property law firm McDonnell Boehnen Hulbert & Berghoff, said that the […]


Patent decision favors BDSI; USPTO rejects 222 MonoSol Rx claims

Specialty pharmaceutical company BioDelivery Sciences International (NASDAQ:BDSI) can now claim patent victories against all three patent challenges levied by a rival in a long-running patent dispute. The U.S. Patent and Trademark Office has rejected all claims made by MonoSol Rx in the third MonoSol patent that the New Jersey company alleged BDSI had infringed. In […]


Patent ruling favors BDSI; MonoSol still claims infringement on other patents

BioDelivery Sciences International (NASDAQ:BDSI) has a patent victory against a competitor who claims the North Carolina pharmaceutical company’s drug delivery platform infringes on its technology. The United States Patent and Trademark Office rejected all 191 claims made by New Jersey-based MonoSol Rx as unpatentable. The dispute centers on the technology that forms BDSI’s drug-delivery platform. […]


Migraine drug patents for Pozen’s Treximet upheld by judge

Migraine headache treatment Treximet, developed by pharmaceutical company Pozen (NASDAQ:POZN), has won a patent victory against generics companies looking to introduce their versions of the drug. A federal judge in Texas has ruled that two Treximet patents are valid and enforceable, and were infringed by Par Pharmaceutical (NYSE:PRX), Alphapharm and Dr. Reddy’s Laboratories (NYSE:RDY). A […]